Pharmacoeconomics of hematopoietic stem cell mobilization: An overview of current evidence and gaps in the literature

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 9, 2013, Pages 1301-1309

  Shaughnessy, Paul ^a   Chao, Nelson ^b   Shapiro, Jamie ^c   Walters, Kent ^d   McCarty, John ^e   Abhyankar, Sunil ^f   Shayani, Sepideh ^g   Helmons, Pieter ^h   Leather, Helen ⁱ   Pazzalia, Amy ⁱ   Pickard, Simon ^j  

^a TEXAS TRANSPLANT INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Moffit University   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g City of Hope   (United States)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

Autologous; Costs; Failure to mobilize; Mobilization; Pharmacoeconomics; Plerixafor

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

APHERESIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL COUNT; COMPASSIONATE USE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL READMISSION; HUMAN; LARGE CELL LYMPHOMA; LENGTH OF STAY; MAINTENANCE CHEMOTHERAPY; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; QUALITY ADJUSTED LIFE YEAR; REVIEW; STEM CELL MOBILIZATION; TERMINAL CARE; ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PHARMACOECONOMICS; PROCEDURES;

ECONOMICS, PHARMACEUTICAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84882776631     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.05.008     Document Type: Review

References (80)

1. Copelan E.A. Hematopoietic stem-cell transplantation. NEngl J Med 2006, 354:1813-1826.
2. Oliansky D.M., Czuczman M., Fisher R.I., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: Update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011, 17:20-47.
3. Oliansky D.M., Gordon L.I., King J., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: An evidence-based review. Biol Blood Marrow Transplant 2010, 16:443-468.
4. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. NEngl J Med 2003, 348:1875-1883.
5. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321. JClin Oncol 2006, 24:929-936.
6. Bladé J., Rosiñol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005, 106:3755-3759.
7. Fermand J., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the group myelome-autogreffe. JClin Oncol 2005, 23:9227-9233.
8. Segeren C.M., Sonneveld P., van der Holt B., et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study. Blood 2003, 101:2144-2151.
9. Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood 2004, 104:3052-3057.
10. Attal M., Harousseau J., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. NEngl J Med 2003, 349:2495-2502.
11. Attal M., Harousseau J., Stoppa A., et al. Aprospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. NEngl J Med 1996, 335:91-97.
12. Gertz M.A. Review: Current status of stem cell mobilization. Br J Haematol 2010, 150:647-662.
13. Meldgaard Knudsen L., Jensen L., Gaarsdal E., et al. Acomparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant 2000, 26:717-722.
14. Zhou P., Zhang Y., Martinez C., et al. Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. Blood 2003, 102:477-479.
15. Smith T.J., Hillner B.E., Schmitz N., et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. JClin Oncol 1997, 15:5-10.
16. Micallef I.N., Inwards D.J., Dispenzieri A., et al. Arisk adapted approach utilizing plerixafor in autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2010, 16:S197-S198.
17. Micallef I.N., Sinha S., Gastineau D.A., et al. Acost effective analysis of a risk-adapted algorithm for plerixafor use in autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2011, 17:S159-S160.
18. Roberts C., Sabo R., Shickle L., et al. Cost-effective stem cell mobilization: A novel early plerixafor salvage strategy is optimally resource-effective compared to chemotherapy, G-CSF or initial plerixafor strategies. Bone Marrow Transplant 2011, 46:S60-S61. [abstract O378].
19. Jagasia M.H., Savani B.N., Neff A., et al. Outcome, toxicity profile and cost analysis of autologous stem cell mobilization. Bone Marrow Transplant 2011, 46:1084-1088.
20. Hosing C., Smith V., Rhodes B., et al. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion 2011, 51:1300-1313.
21. Shaughnessy P., Islas-Ohlmayer M., Murphy J., et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011, 17:729-736.
22. Gabriel I.H., Sharon J., Olavarria E., et al. Efficacy, complication rates, and cost effectiveness of chemotherapy plus granulocyte colony stimulating factor conditioned mobilisation of peripheral blood haematopoietic stem cells in over 150 patients with haematological malignancies. Blood 2008, 112:2378.
23. Bacon W.A., Long G.D., Rizzieri D.A., et al. Impact of high dose cyclophosphamide on the outcome of autologous stem cell transplant in patients with newly diagnosed multiple myeloma. Blood 2011, 118:4127.
24. Chao N.J., Grima D.T., Carrum G., et al. Chemo-mobilization provides superior mobilization and collection in autologous stem cell transplants but with less predictability and at a higher cost. Blood 2011, 118:4048.
25. Hosing C., Saliba R.M., Ahlawat S., et al. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009, 84:335-337.
26. Basak G.W., Jaksic O., Koristek Z., et al. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol 2011, 86:550-553.
27. Stiff P.J. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999, 23(Suppl 2):S29-S33.
28. Micallef I.N., Apostolidis J., Rohatiner A.Z., et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000, 1:367-373.
29. Wuchter P., Ran D., Bruckner T., et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010, 16:490-499.
30. Bensinger W., Appelbaum F., Rowley S., et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. JClin Oncol 1995, 1325:2547-2555.
31. Haas R., Mohle R., Fruhauf S., et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994, 83:3787-3794.
32. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
33. Paripati H., Stewart A.K., Cabou S., et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008, 22:1282-1284.
34. Mazumder A., Kaufman J., Niesvizky R., et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008, 22:1280-1281. author reply 1281-1282.
35. Cavallo F., Bringhen S., Milone G., et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia 2011, 25:1627-1631.
36. Tournilhac O., Cazin B., Leprètre S., et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004, 103:363-365.
37. Waterman J., Rybicki L., Bolwell B., et al. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant 2012, 47:488-493.
38. Popat U., Saliba R., Thandi R., et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009, 15:718-723.
39. Pusic I., Jiang S.Y., Landua S., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
40. Pavone V., Gaudio F., Console G., et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:719-724.
41. Bensinger W., DiPersio J.F., McCarty J.M. Improving stem cell mobilization strategies: Future directions. Bone Marrow Transplant 2009, 43:181-195.
42. Gertz M.A., Wolf R.C., Micallef I.N., Gastineau D.A. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010, 45:1396-1403.
43. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
44. Jakubowiak A.J., Griffith K.A., Reece D.E., et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: A phase 1/2 multiple myeloma research consortium trial. Blood 2011, 118:535-543.
45. Moreau P., Hulin C., Marit G., et al. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia 2010, 24:1233-1235.
46. Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. JClin Oncol 2010, 28:4184-4190.
47. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with invivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
48. Damon L.E., Johnson J.L., Niedzwiecki D., et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. JClin Oncol 2009, 27:6101-6108.
49. Gazitt Y., Freytes C.O., Callander N., et al. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. JHematother 1999, 8:173-183.
50. Kobbe G., Sohngen D., Bauser U., et al. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma. Ann Hematol 1999, 78:456-462.
51. Weaver C.H., Birch R., Greco F.A., et al. Mobilization and harvesting of peripheral blood stem cells: Randomized evaluations of different doses of filgrastim. Br J Haematol 1998, 100:338-347.
52. Winter J.N., Lazarus H.M., Rademaker A., et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. JClin Oncol 1996, 14:277-286.
53. Madero L., Gonzalez-Vicent M., Molina J., et al. Use of concurrent G-CSF+ GM-CSF versus G-CSF alone for mobilization of peripheral blood stem cells in children with malignant disease. Bone Marrow Transplant 2000, 26:365-369.
54. Bashey A., Corringham S., Fields K. Use of concurrent GM-CSF and G-CSF administration to re-mobilize patients who fail initial mobilization: results on twenty-three patients from two centers. Blood 1999, 94(Suppl 1):327a.
55. Boeve S., Strupeck J., Creech S., Stiff P.J. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: Risk factors, cytokine use and cost. Bone Marrow Transplant 2004, 33:997-1003.
56. Woronoff-Lemsi M.C., Arveux P., Limat S., et al. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. Bone Marrow Transplant 1997, 20:975-982.
57. Glaspy J.A. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant 1999, 23:S21-S27.
58. Vellenga E., Van Agthoven M., Croockewit A.J., et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: The hovon 22 study. Br J Haematol 2001, 114:319-326.
59. + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
60. DiPersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. JClin Oncol 2009, 27:4767-4773.
61. + cells in autologous hematopoietic cell transplant candidates. Blood 2011, 118:4060.
62. Vishnu P., Roy V., Paulsen A., Zubair A.C. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012, 52:55-62.
63. Li J., Hamilton E., Vaughn L., et al. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011, 51:2175-2182.
64. LaPorte J., Solomon S.R., Bashey A., et al. An effective hematopoietic stem cell mobilization algorithm for adding plerixafor to G-CSF for multiple myeloma patients undergoing autologous transplantation. Blood 2011, 118:4389.
65. Abhyankar S., Dejarnette S., Aljitawi O., et al. Arisk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2012, 47:483-487.
66. Costa L.J., Alexander E.T., Hogan K.R., et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011, 46:64-69.
67. Costa L.J., Miller A.N., Alexander E.T., et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011, 46:523-528.
68. Micallef I.N., Sinha S., Gastineau D.A., et al. Cost effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2013, 19:87-93.
69. Drummond M.F., Sculpher M., Torrance G., et al. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford; New York. 3rd ed.
70. Siegel J.E., Torrance G.W., Russell L.B., et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997, 11:159-168.
71. Weinstein M.C., Siegel J.E., Gold M.R., et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996, 276:1253-1258.
72. Whitehead S.J., Ali S. Health outcomes in economic evaluation: The QALY and utilities. British Medical Bulletin 2010, 96:5-21.
73. Normand C. Measuring outcomes in palliative care: Limitations ofQALYs and the road to PalYs. JPain Symptom Manage 2009, 38:27-31.
74. Campen C.J., Armstrong E.P., Christian J.A., et al. Comparative cost-effectiveness of plerixafor plus granulocyte-colony stimulating factor versus cyclophosphamide plus granulocyte-colony stimulating for autologous peripheral blood stem cell mobilization in patients withnon-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2010, 16:S206.
75. Adel N.G., Duck E., Collum K., et al. Cost analysis of using plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients treated at Memorial Sloan-Kettering cancer center (MSKCC). Blood 2011, 118:4059.
76. Isola L., Banoff K.M., Kim S.S. Pharmacoeconomic impact of upfront use plerixafor for autologous stem cell mobilization in multiple myeloma patients. Blood 2011, 118:2075.
77. Perkins J., Bookout R., Sapiro J., et al. Retrospective comparison of secondary mobilization strategies in candidates for autologous hematopoietic cell transplantion with a focus on resource utilization: Plerixafor+ G-CSF versus other regimens. Biol Blood Marrow Transplant 2010, 16:S201. Abstract 118.
78. Kymes S.M., Pusic I., Lambert D.L., et al. Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care 2012, 18:33-41.
79. Giralt S., Stadtmauer E.A., Harousseau J.L., et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009, 23:1904-1912.
80. Chen A.I., Bains T., Murray S., et al. Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplant 2012, 47:1526-1529.